0001213900-22-035699.txt : 20220629 0001213900-22-035699.hdr.sgml : 20220629 20220629083231 ACCESSION NUMBER: 0001213900-22-035699 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220629 FILED AS OF DATE: 20220629 DATE AS OF CHANGE: 20220629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroSense Therapeutics Ltd. CENTRAL INDEX KEY: 0001875091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41084 FILM NUMBER: 221051897 BUSINESS ADDRESS: STREET 1: 11 HAMENOFIM ST. STREET 2: BUILDING B CITY: HERZLIYA STATE: L3 ZIP: 4672562 BUSINESS PHONE: 972-9-9531142 MAIL ADDRESS: STREET 1: 11 HAMENOFIM ST. STREET 2: BUILDING B CITY: HERZLIYA STATE: L3 ZIP: 4672562 6-K 1 ea162237-6k_neurosense.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of June 2022

 

Commission File Number: 001-41084

 

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

 

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

NeuroSense Therapeutics reports completion of the "in-life" phase of its 90-day GLP Toxicology study successfully. All animals appeared normal, with no significant findings observed. In this study the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. The company will present the data obtained in this study to the FDA as part of PrimeC's drug development plan.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NeuroSense Therapeutics Ltd.
     
Date: June 29, 2022 By: /s/ Alon Ben-Noon
    Alon Ben-Noon
Chief Executive Officer

 

 

2